Comments
Loading...

Lineage Cell Therapeutics

LCTXAMEX
Logo brought to you by Benzinga Data
$0.571900
0.00310.55%
At close: -
$0.608400
0.046.38%
After Hours: Nov 29, 4:47 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$7.00
Lowest Price Target1
$2.00
Consensus Price Target1
$5.00

Lineage Cell Therapeutics (AMEX:LCTX) Stock, Analyst Ratings, Price Targets, Forecasts

Lineage Cell Therapeutics Inc has a consensus price target of $5 based on the ratings of 7 analysts. The high is $7 issued by HC Wainwright & Co. on May 6, 2024. The low is $2 issued by D. Boral Capital on November 20, 2024. The 3 most-recent analyst ratings were released by D. Boral Capital, D. Boral Capital, and Craig-Hallum on November 20, 2024, November 18, 2024, and August 20, 2024, respectively. With an average price target of $3 between D. Boral Capital, D. Boral Capital, and Craig-Hallum, there's an implied 424.57% upside for Lineage Cell Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Aug
2
Nov
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

D. Boral Capital
Craig-Hallum
HC Wainwright & Co.
Cantor Fitzgerald
HC Wainwright & Co.

1calculated from analyst ratings

Analyst Ratings for Lineage Cell Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Lineage Cell Therapeutics (LCTX) stock?

A

The latest price target for Lineage Cell Therapeutics (AMEX:LCTX) was reported by D. Boral Capital on November 20, 2024. The analyst firm set a price target for $2.00 expecting LCTX to rise to within 12 months (a possible 249.71% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Lineage Cell Therapeutics (LCTX)?

A

The latest analyst rating for Lineage Cell Therapeutics (AMEX:LCTX) was provided by D. Boral Capital, and Lineage Cell Therapeutics maintained their buy rating.

Q

When was the last upgrade for Lineage Cell Therapeutics (LCTX)?

A

There is no last upgrade for Lineage Cell Therapeutics

Q

When was the last downgrade for Lineage Cell Therapeutics (LCTX)?

A

There is no last downgrade for Lineage Cell Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Lineage Cell Therapeutics (LCTX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lineage Cell Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lineage Cell Therapeutics was filed on November 20, 2024 so you should expect the next rating to be made available sometime around November 20, 2025.

Q

Is the Analyst Rating Lineage Cell Therapeutics (LCTX) correct?

A

While ratings are subjective and will change, the latest Lineage Cell Therapeutics (LCTX) rating was a maintained with a price target of $3.00 to $2.00. The current price Lineage Cell Therapeutics (LCTX) is trading at is $0.57, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch